<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842906</url>
  </required_header>
  <id_info>
    <org_study_id>SLEEP-AID</org_study_id>
    <nct_id>NCT01842906</nct_id>
  </id_info>
  <brief_title>Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)</brief_title>
  <acronym>SLEEP-AID</acronym>
  <official_title>Randomized Controlled Trial for Assessment of a Novel Non-Pharmacologic Intervention for Decrease in Altitude Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is examining if an over-the-counter device (Theravent) worn while sleeping can
      reduce acute mountain sickness upon awakening in a high altitude trekking population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aim of this study is to evaluate if an inexpensive and disposable end-expiratory
      pressure device can prevent acute mountain sickness (AMS). AMS is a common disorder found in
      25-75% of hikers and trekkers in N. America and Europe who expediently ascend high altitude
      (&gt;8,000 ft). This environmental malady is insidious in onset and prevention is necessary not
      just to limit progression to severe or fatal disease, but also to limit physiologic
      deterioration in those who seek enjoyment or employment at high altitudes. One of the
      hallmarks of both healthy and sick individuals sleeping at high altitude is an oscillating
      pattern of respiration marked by periods of hyperventilation alternating with apnea or
      hypopnea. This distressing &quot;periodic breathing&quot; pattern leads to a feeling of suffocation,
      prevents restful sleep, and the hypoxic events may well worsen ensuing AMS. Prior studies
      have found positive end-expiratory pressure (PEEP) an effective non-pharmacologic method to
      prevent nocturnal desaturations and decreasing both AMS incidence and severity.

      Traditionally, PEEP devices are cumbersome and expensive, and while showing promising
      efficacy, are limited by both cost and portability as a useful non-pharmacologic option for
      AMS prophylaxis. The SLEEP-AID methodology is designed to prospectively enroll participants,
      randomized in a double blind placebo-controlled fashion to either the intervention [Theravent
      (Ventus Medical) which is single use, inexpensive, and very small] or a visually identical
      &quot;sham&quot; placebo group, and gather physiologic data to accurately reflect sleep patterns of
      high altitude travelers and objective as well as subjective outcomes of the intervention. The
      benefit of this approach will be to provide definitive data in a large and diverse cross
      section of a real hiking population that is generalizable to the majority of tens of millions
      of hikers, climbers, and high altitude tourists in the United States, Europe, Asia, and South
      America.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Mountain Sickness</measure>
    <time_frame>Approximately 10 hours</time_frame>
    <description>Acute mountain sickness will be measured by Lake Louise Criteria and diagnosed as LLC &gt; or = to 3 with presence of a headache. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Nocturnal Desaturations</measure>
    <time_frame>Approximately 10 hours</time_frame>
    <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Mountain Sickness Severity</measure>
    <time_frame>approximately 10 hours</time_frame>
    <description>Severity of acute mountain sickness will be evaluated by the Lake Louise Criteria (0-15 point scale) with higher scores representing more severe symptoms. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Awakenings</measure>
    <time_frame>approximately 10 hours</time_frame>
    <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Acute Mountain Sickness</condition>
  <arm_group>
    <arm_group_label>Theravent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A visibly identical sham device that does not provide positive end expiratory pressure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theravent</intervention_name>
    <description>nasal EPAP device</description>
    <arm_group_label>Theravent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Sham device without EPAP</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-65

          -  Lake Louise Score (LLS) of &lt; 3

          -  Have not taken NSAIDs, acetazolamide, or corticosteroids in the prior week

          -  Have not traveled above 4200 m in the prior week.

          -  First night in Pheriche or Dingboche

        Exclusion Criteria:

          -  Unable to read the consent form

          -  Taken NSAIDs, acetazolamide, or corticosteroids in the week prior to study enrollment.

          -  Hazardous medical conditions which precludes the ability to tolerate the experimental
             device.

          -  Pregnancy or suspected pregnancy.

          -  Participants who are younger than 18 years of age and more than 65.

          -  Travel to or above 4200m in the preceding week.

          -  Diagnosis of AMS upon enrollment (LLS â‰¥3 with symptoms of headache)

          -  Previously diagnosed obstructive sleep apnea

          -  Current symptoms of nasal congestion, rhinorrhea, sinusitis, upper respiratory
             infection, asthma, COPD exacerbation, pneumonia, bronchitis, or other disease of the
             respiratory tract.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant S Lipman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nepal</name>
      <address>
        <city>Pheriche &amp; Dingboche</city>
        <state>Khumbu</state>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <results_first_submitted>August 9, 2016</results_first_submitted>
  <results_first_submitted_qc>March 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2017</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Grant S Lipman</investigator_full_name>
    <investigator_title>Clinical Associate Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>positive end expiratory pressure</keyword>
  <keyword>acute mountain sickness</keyword>
  <keyword>prevention</keyword>
  <keyword>high altitude</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Theravent</title>
          <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Theravent</title>
          <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="6"/>
                    <measurement group_id="B2" value="37" spread="8"/>
                    <measurement group_id="B3" value="38" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nepal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Mountain Sickness</title>
        <description>Acute mountain sickness will be measured by Lake Louise Criteria and diagnosed as LLC &gt; or = to 3 with presence of a headache. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
        <time_frame>Approximately 10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
          </group>
          <group group_id="O2">
            <title>Theravent</title>
            <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Mountain Sickness</title>
          <description>Acute mountain sickness will be measured by Lake Louise Criteria and diagnosed as LLC &gt; or = to 3 with presence of a headache. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Nocturnal Desaturations</title>
        <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
        <time_frame>Approximately 10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
          </group>
          <group group_id="O2">
            <title>Theravent</title>
            <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nocturnal Desaturations</title>
          <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
          <units>Number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" spread="226"/>
                    <measurement group_id="O2" value="214" spread="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Mountain Sickness Severity</title>
        <description>Severity of acute mountain sickness will be evaluated by the Lake Louise Criteria (0-15 point scale) with higher scores representing more severe symptoms. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
        <time_frame>approximately 10 hours</time_frame>
        <population>Severity</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
          </group>
          <group group_id="O2">
            <title>Theravent</title>
            <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Mountain Sickness Severity</title>
          <description>Severity of acute mountain sickness will be evaluated by the Lake Louise Criteria (0-15 point scale) with higher scores representing more severe symptoms. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
          <population>Severity</population>
          <units>unit on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.049" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.13" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.058" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Awakenings</title>
        <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
        <time_frame>approximately 10 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
          </group>
          <group group_id="O2">
            <title>Theravent</title>
            <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Awakenings</title>
          <description>Number of nocturnal desaturations will be measured by Watch-PAT200, a wristwatch type continuous sleep cycle and pulse oximetry analyzer. Study participants will be followed approximately for 10 hours, from when they go to sleep until awakening the next morning.</description>
          <units>Number of events</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="O2" value="13" lower_limit="7" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months (duration of study and intervention)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>A visibly identical sham device that does not provide positive end expiratory pressure.
Control: Sham device without EPAP</description>
        </group>
        <group group_id="E2">
          <title>Theravent</title>
          <description>A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
Theravent: nasal EPAP device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Lipman</name_or_title>
      <organization>Stanford Department of Emergency Medicine</organization>
      <phone>415-290-9286</phone>
      <email>gslipman@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

